AU2019317625B2 - Pyrrolopyrimidine ITK inhibitors - Google Patents

Pyrrolopyrimidine ITK inhibitors Download PDF

Info

Publication number
AU2019317625B2
AU2019317625B2 AU2019317625A AU2019317625A AU2019317625B2 AU 2019317625 B2 AU2019317625 B2 AU 2019317625B2 AU 2019317625 A AU2019317625 A AU 2019317625A AU 2019317625 A AU2019317625 A AU 2019317625A AU 2019317625 B2 AU2019317625 B2 AU 2019317625B2
Authority
AU
Australia
Prior art keywords
pyrrolo
amino
pyrimidin
prop
methylpiperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019317625A
Other languages
English (en)
Other versions
AU2019317625A1 (en
Inventor
David Anderson
James Blinn
Richard HEIER
Susan Hockerman
Eric Jacobsen
Paramita MUKHERJEE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aclaris Therapeutics Inc
Original Assignee
Aclaris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aclaris Therapeutics Inc filed Critical Aclaris Therapeutics Inc
Publication of AU2019317625A1 publication Critical patent/AU2019317625A1/en
Application granted granted Critical
Publication of AU2019317625B2 publication Critical patent/AU2019317625B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019317625A 2018-08-10 2019-08-12 Pyrrolopyrimidine ITK inhibitors Active AU2019317625B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862717400P 2018-08-10 2018-08-10
US62/717,400 2018-08-10
PCT/US2019/046182 WO2020033955A1 (en) 2018-08-10 2019-08-12 Pyrrolopyrimidine itk inhibitors

Publications (2)

Publication Number Publication Date
AU2019317625A1 AU2019317625A1 (en) 2021-02-18
AU2019317625B2 true AU2019317625B2 (en) 2025-02-27

Family

ID=69405523

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019317625A Active AU2019317625B2 (en) 2018-08-10 2019-08-12 Pyrrolopyrimidine ITK inhibitors

Country Status (13)

Country Link
US (4) US11021482B2 (OSRAM)
EP (1) EP3833350A4 (OSRAM)
JP (2) JP7591500B2 (OSRAM)
KR (1) KR102849047B1 (OSRAM)
CN (2) CN112823005B (OSRAM)
AU (1) AU2019317625B2 (OSRAM)
BR (1) BR112021002479A2 (OSRAM)
CA (1) CA3109192A1 (OSRAM)
IL (1) IL280593A (OSRAM)
MX (1) MX2021001558A (OSRAM)
PH (1) PH12021550187A1 (OSRAM)
SG (1) SG11202100525SA (OSRAM)
WO (1) WO2020033955A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102821964B1 (ko) 2017-11-03 2025-06-19 어클라리스 쎄라퓨틱스, 인코포레이티드 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법
EP3833350A4 (en) 2018-08-10 2022-05-18 Aclaris Therapeutics, Inc. Pyrrolopyrimidine itk inhibitors
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
US11420966B2 (en) 2019-05-02 2022-08-23 Aclaris Therapeutics, Inc. Substituted pyrrolopyridines as JAK inhibitors
CN114787363A (zh) 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达
JP2023528239A (ja) * 2020-05-14 2023-07-04 テラバンス バイオファーマ アールアンドディー アイピー リミテッド ライアビリティ カンパニー 腸管選択的ｊａｋ３阻害剤の投与
KR102560138B1 (ko) * 2020-06-15 2023-07-27 경북대학교 산학협력단 신경교세포 표현형 기반의 siRNA 다중 스크리닝을 통해 선별된 신경교세포 인산화효소의 신경염증 조절 용도
CN114887080B (zh) * 2020-12-08 2023-10-31 深圳瑞吉生物科技有限公司 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用
CN113350346B (zh) * 2021-06-01 2023-06-27 广西医科大学第一附属医院 长春新碱在预防或治疗心肌纤维化中的应用
WO2023014049A1 (ko) * 2021-08-02 2023-02-09 한국화학연구원 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물
CN113571191A (zh) * 2021-08-31 2021-10-29 复旦大学附属中山医院 免疫检查点抑制剂相关mace发生风险的预测方法
WO2023110843A1 (en) * 2021-12-15 2023-06-22 Almirall, S.A. Heterobicyclic derivatives as itk inhibitors
WO2023130078A2 (en) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Genetically modified mycelium for producing psychotropic alkaloids
EP4615440A1 (en) * 2022-11-08 2025-09-17 Aclaris Therapeutics, Inc. Pyrrolopyrimidine compositions for treatment of itk mediated conditions
CN116115760A (zh) * 2022-12-15 2023-05-16 浙江大学 Eed抑制剂在制备治疗神经免疫性疾病药物中的应用
WO2025144783A1 (en) * 2023-12-28 2025-07-03 Aclaris Therapeutics, Inc. Methods of synthesizing substituted pyrrolopyrimidine compounds
WO2025144781A1 (en) * 2023-12-28 2025-07-03 Aclaris Therapeutics, Inc. Crystalline polymorph of an itk inhibitor
CN117982685B (zh) * 2024-01-26 2025-05-30 北京大学人民医院 用于骨肉瘤检测的光学分子成像探针及其制备方法和应用
WO2025181247A1 (en) * 2024-02-28 2025-09-04 Almirall, S.A. Heterobicyclic derivatives as itk inhibitors
WO2025235366A1 (en) * 2024-05-07 2025-11-13 Aclaris Therapeutics, Inc. Pyrrolopyrimidine compositions for treatment of atopic dermatitis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013085802A1 (en) * 2011-12-06 2013-06-13 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
US20150158864A1 (en) * 2013-12-05 2015-06-11 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyr-rolo[2,3-d]pyridinyl acrylamides
WO2016000615A1 (en) * 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Heteroaryl compounds and pharmaceutical applications thereof
WO2016178110A1 (en) * 2015-05-01 2016-11-10 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
WO2018004306A1 (en) * 2016-06-30 2018-01-04 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
US20180055846A1 (en) * 2016-08-24 2018-03-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO118291B1 (ro) 1993-11-30 2003-04-30 Searle & Co Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EP1091739A1 (en) 1998-06-30 2001-04-18 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
SE0301372D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
KR20080016659A (ko) 2005-05-20 2008-02-21 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 피롤로피리딘
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
KR20080026654A (ko) 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
TW200900061A (en) 2007-01-12 2009-01-01 Astellas Pharma Inc Condensed pyridine compound
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
BR112014002472A2 (pt) 2011-08-12 2017-04-11 Nissan Chemical Ind Ltd "compostos heterocíclicos tricíclicos, seu uso, agente terapêutico para reumatismo articular e medicamento"
KR102576903B1 (ko) 2012-09-07 2023-09-13 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
GB2515785A (en) * 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
CN106459048A (zh) 2014-05-14 2017-02-22 辉瑞公司 吡唑并吡啶类和吡唑并嘧啶类
CN105712998B (zh) * 2014-12-05 2019-12-13 上海润诺生物科技有限公司 氮杂吲哚类衍生物、其制备方法及其在医药上的应用
HK1245677A1 (zh) * 2015-01-23 2018-08-31 Aclaris Therapeutics, Inc. 用於治疗炎症和癌症的杂环itk抑制剂
ES2830446T3 (es) 2015-12-11 2021-06-03 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Derivado de azetidina, método de preparación del mismo y uso del mismo
US10800775B2 (en) 2017-11-03 2020-10-13 Aclaris Therapeutics, Inc. Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
KR102821964B1 (ko) 2017-11-03 2025-06-19 어클라리스 쎄라퓨틱스, 인코포레이티드 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법
EP3833350A4 (en) * 2018-08-10 2022-05-18 Aclaris Therapeutics, Inc. Pyrrolopyrimidine itk inhibitors
US11596632B2 (en) 2018-12-19 2023-03-07 Incyte Corporation JAK1 pathway inhibitors for the treatment of gastrointestinal disease
US11420966B2 (en) 2019-05-02 2022-08-23 Aclaris Therapeutics, Inc. Substituted pyrrolopyridines as JAK inhibitors
JP7532511B2 (ja) 2019-06-10 2024-08-13 インサイト・コーポレイション Ｊａｋ阻害剤による尋常性白斑の局所治療
WO2021022178A1 (en) 2019-07-31 2021-02-04 Aclaris Therapeutics, Inc. Substituted sulfonamide pyrrolopyridines as jak inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013085802A1 (en) * 2011-12-06 2013-06-13 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
US20150158864A1 (en) * 2013-12-05 2015-06-11 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyr-rolo[2,3-d]pyridinyl acrylamides
WO2016000615A1 (en) * 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Heteroaryl compounds and pharmaceutical applications thereof
WO2016178110A1 (en) * 2015-05-01 2016-11-10 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
WO2018004306A1 (en) * 2016-06-30 2018-01-04 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
US20180055846A1 (en) * 2016-08-24 2018-03-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof

Also Published As

Publication number Publication date
US20260035373A1 (en) 2026-02-05
JP2021534244A (ja) 2021-12-09
US11820775B2 (en) 2023-11-21
BR112021002479A2 (pt) 2021-07-27
EP3833350A1 (en) 2021-06-16
US12297203B2 (en) 2025-05-13
PH12021550187A1 (en) 2022-02-14
US20200048262A1 (en) 2020-02-13
MX2021001558A (es) 2021-04-28
JP7591500B2 (ja) 2024-11-28
US11021482B2 (en) 2021-06-01
KR20210044822A (ko) 2021-04-23
CA3109192A1 (en) 2020-02-13
SG11202100525SA (en) 2021-02-25
CN112823005B (zh) 2024-08-20
US20240132505A1 (en) 2024-04-25
CN112823005A (zh) 2021-05-18
CN119080779A (zh) 2024-12-06
EP3833350A4 (en) 2022-05-18
US20220348579A1 (en) 2022-11-03
JP2025037892A (ja) 2025-03-18
AU2019317625A1 (en) 2021-02-18
IL280593A (en) 2021-03-25
KR102849047B1 (ko) 2025-08-22
WO2020033955A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
US12297203B2 (en) Pyrrolopyrimidine ITK inhibitors
AU2023248127B2 (en) Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
US11434233B2 (en) Heterocyclic inhibitors of ATR kinase
WO2021022186A1 (en) Deuterated mk2 pathway inhibitors and methods of using the same
JP2019535664A (ja) ユビキチン特異的プロテアーゼ７の阻害剤としてのピペリジン誘導体
WO2019090143A1 (en) Pyrazolyl pyrrolo[2,3-b]pyrimidine-5-carboxylate analogs and methods of making the same
WO2021022178A1 (en) Substituted sulfonamide pyrrolopyridines as jak inhibitors
WO2019178590A1 (en) Heterocyclic inhibitors of atr kinase
US10316038B2 (en) Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer
HK40028148A (en) Heterocyclic inhibitors of atr kinase
HK40028148B (en) Heterocyclic inhibitors of atr kinase

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)